Table 2 Cost-effectiveness rankings of strategies
Strategy | Total costs | Total QALYs | ICER vs Omalizumab |
|---|---|---|---|
1) Omalizumab | $168,414 | 5.34 | – |
2) Dupilumab | $207,453 | 5.51 | $235,305/QALY |
3) Mepolizumab | $217,280 | 5.13 | Dominated by Omalizumab |
Strategy | Total costs | Total QALYs | ICER vs Omalizumab |
|---|---|---|---|
1) Omalizumab | $168,414 | 5.34 | – |
2) Dupilumab | $207,453 | 5.51 | $235,305/QALY |
3) Mepolizumab | $217,280 | 5.13 | Dominated by Omalizumab |